Certara (CERT) Projected to Release Earnings on Tuesday

Certara (NASDAQ:CERT) is expected to be releasing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of $0.10 per share and revenue of $98.0870 million for the quarter. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Investors may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Certara (NASDAQ:CERT) last issued its earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The firm had revenue of $106.92 million during the quarter, compared to the consensus estimate of $106.13 million. During the same quarter in the prior year, the company posted $0.14 EPS. The company’s quarterly revenue was up .8% on a year-over-year basis. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Certara Trading Up 4.1%

NASDAQ:CERT opened at $8.10 on Friday. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -81.00 and a beta of 1.46. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. The company’s 50 day moving average price is $6.30 and its 200-day moving average price is $6.60. Certara has a 52 week low of $4.45 and a 52 week high of $13.88.

Institutional Trading of Certara

Large investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. increased its position in Certara by 2,733.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after acquiring an additional 2,870 shares during the last quarter. Osaic Holdings Inc. boosted its position in Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of Certara during the 2nd quarter valued at about $83,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Certara during the 4th quarter valued at about $92,000. Institutional investors own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Stephens lowered their price objective on Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. BMO Capital Markets reduced their target price on Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Tuesday, May 12th. Morgan Stanley decreased their price target on Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Robert W. Baird decreased their price target on Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th. Finally, KeyCorp lowered their price target on Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.85.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.